Obermatt

Syngene International

NSI:SYNGENE · INE398R01022
Life Sciences Tools & ServicesMedium

360

78
EV / EBIT15
Price / Owner Earnings28
Owner Earnings Yield79
Dividend Yield33
Price/Sales30
EV / Gross Profit83
Price/Book37
Return on Capital70
Cash Return on Capital85
Return on Equity72
EBIT Margin68
Gross Profitability88
Cash Conversion74
Owner Earnings Margin76
Sales growth34
Profit Growth20
Long-Term EPS Growth91
Reinvestment22
Price momentum11
Debt load65
Refinancing6
Debt Payback100
Liquidity48
Analyst ratings33
Opinion Changes50
Price Target Upside67
Market mood81
Value Creation3/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Syngene International doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Based on 3/5 components.

Profile

CountryIndia
IndustryLife Sciences Tools & Services
SizeMedium
TypePublic Company
ExchangeNSEI
Founded1993
Employees5,965
ISININE398R01022
Last UpdateApr 2, 2026
Index & Theme
Health DiagnosticsPharmacovigilanceGeneticsBiometricsOncologyManufacturingPharmaceutical

Description

Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services. The company engages in providing scientific solutions through integrated research, development, and manufacturing services…

Analysis

Quality compounder

Syngene International Limited is a quality compounder: a well-run business trading at a price that reflects what it is worth.

The price is expensive. You pay 38.5× its owner earnings: the cash an owner could take out each year, which is in the historically expensive zone. At today's price, the market is assuming roughly 15% yearly growth; analysts expect 23%. The price, in other words, assumes less than the experts do.

The trajectory is moderate and the balance sheet is sturdy. The company scores 3/20 on our value-creation score: not creating value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
6
2023202420252026

All-time high

19

Jan 2023

All-time low

4

Jan 2025

Average rank

9

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
30
25
22
9
Price/Earnings
12
15
12
9
Price/Book
37
28
28
19
Dividend Yield
33
14
15
17
Value (overall)
20
13
10
3

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Syngene International with its peers
Adlai Nortye
NMQ:ANL
17
CountryCayman Islands
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Glenmark Pharmaceuticals
NSI:GLENMARK
58
CountryIndia
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Laurus Labs
NSI:LAURUSLABS
28
CountryIndia
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Jubilant Life Sciences
NSI:JUBLPHARMA
47
CountryIndia
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Netcare
JNB:NTC
87
CountrySouth Africa
IndustryHealth Care Providers & Services
SizeLarge
Full Stock Analysis →
Lupin
NSI:LUPIN
67
CountryIndia
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →